Kerill Pochetuhen
Family Medicine · Brooklyn, NYNPI 1326456088
Payments from drug & device makers
Across 190 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$822
- Lilly USA, LLC$317
- GSK$311
- Ardelyx, Inc.$290
- Novo Nordisk$252
- E.r. Squibb & Sons, L.L.C.$240
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,921100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $822 |
| Lilly USA, LLC | 15 | $317 |
| GSK | 13 | $311 |
| Ardelyx, Inc. | 14 | $290 |
| Novo Nordisk | 12 | $252 |
| E.r. Squibb & Sons, L.L.C. | 14 | $240 |
| Novartis | 9 | $178 |
| Aimmune Therapeutics, Inc. | 5 | $175 |
| Idorsia Pharmaceuticals US Inc | 9 | $154 |
| Nestle Healthcare Nutrition Inc. | 7 | $145 |
| Amgen | 7 | $141 |
| Exact Sciences | 5 | $127 |
| Merck | 6 | $125 |
| Pfizer | 5 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $89 |
| AstraZeneca | 4 | $80 |
| Johnson & Johnson | 1 | $50 |
| Kowa Pharmaceuticals America, Inc. | 2 | $41 |
| Boehringer Ingelheim | 2 | $41 |
| Astellas Pharma US Inc | 2 | $40 |
| Tactile Systems Technology Inc | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Shield Therapeutics Inc | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Gilead | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
How this compares
$3,921 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $83,964 |
| LinzessLinaclotide | 135 | $76,845 |
| JanuviaSitagliptin Phosphate | 60 | $74,061 |
| Diclofenac Sodium | 113 | $58,858 |
| ZenpepLipase/Protease/Amylase | 65 | $57,921 |
| CreonLipase/Protease/Amylase | 45 | $55,727 |
| JardianceEmpagliflozin | 68 | $54,899 |
| VascepaIcosapent Ethyl | 139 | $50,350 |
| EliquisApixaban | 55 | $37,755 |
| JanumetSitagliptin Phos/Metformin Hcl | 48 | $29,865 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $27,714 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 23 | $25,096 |
| TradjentaLinagliptin | 42 | $22,875 |
| XareltoRivaroxaban | 26 | $19,945 |
| FarxigaDapagliflozin Propanediol | 27 | $17,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Namzaric, Synthroid | $822 | $142,058237 claims |
| MerckJanuvia, Janumet, Janumet Xr | $125 | $118,492132 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr | $41 | $93,346136 claims |
| Novo NordiskOzempic | $252 | $83,96466 claims |
| Aimmune Therapeutics, Inc.Zenpep | $175 | $57,92165 claims |
| PfizerEliquis | $97 | $37,75555 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $311 | $35,62663 claims |
| Johnson & JohnsonXarelto | $50 | $19,94526 claims |
| AstraZenecaFarxiga | $80 | $17,19927 claims |
| NovartisEntresto | $178 | $15,18017 claims |
| Lilly USA, LLCMounjaro | $317 | $13,35313 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $11,51424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Brooklyn
- Michael YuryevBrooklyn$589K
- Matthew SpitzerBrooklyn$469K
- Walford LindoBrooklyn$104K
- Fu Fu HeBrooklyn$101K
- Jonathan ChangBrooklyn$66K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.